Table 2.
Preclinical study of A COVID-19 mRNA vaccine (from https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines, 30 August 2022).
| Vaccine platform description | Type of candidate vaccine | Coronavirus target | Same platform for non-Coronavirus candidates | Developers |
|---|---|---|---|---|
| RNA based | saRNA formulated in a NLC | SARS-CoV2 | Infectious Disease Research Institute/ Amyris, Inc. | |
| RNA based | LNP-encapsulated mRNA encoding S | SARS-CoV2 | Max-Planck-Institute of Colloids and Interfaces | |
| RNA based | Self-amplifying RNA | SARS-CoV2 | Gennova | |
| RNA based | mRNA | SARS-CoV2 | Selcuk University | |
| RNA based | LNP-mRNA | SARS-CoV2 | Translate Bio/Sanofi Pasteur | |
| RNA based | LNP-mRNA | SARS-CoV2 | CanSino Biologics/Precision NanoSystems | |
| RNA based | LNP-encapsulated mRNA cocktail encoding VLP | SARS-CoV2 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | |
| RNA based | LNP-encapsulated mRNA encoding RBD | SARS-CoV2 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | |
| RNA based | Replicating Defective SARS-CoV-2 derived RNAs | SARS-CoV2 | Centro Nacional Biotecnología (CNB-CSIC), Spain | |
| RNA based | LNP-encapsulated mRNA | SARS-CoV2 | MERS | University of Tokyo/ Daiichi-Sankyo |
| RNA based | Liposome-encapsulated mRNA | SARS-CoV2 | BIOCAD | |
| RNA based | Several mRNA candidates | SARS-CoV2 | RNAimmune, Inc. | |
| RNA based | mRNA | SARS-CoV2 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | |
| RNA based | mRNA | SARS-CoV2 | China CDC/Tongji University/Stermina | |
| RNA based | mRNA in an intranasal delivery system | SARS-CoV2 | eTheRNA | |
| RNA based | mRNA | SARS-CoV2 | Greenlight Biosciences | |
| RNA based | mRNA | SARS-CoV2 | IDIBAPS-Hospital Clinic, Spain | |
| RNA based | mRNA | SARS-CoV2 | Providence Therapeutics | |
| RNA based | mRNA | SARS-CoV2 | Cell Tech Pharmed | |
| RNA based | mRNA | SARS-CoV2 | ReNAP Co. | |
| RNA based | D614G variant LNP-encapsulated mRNA | SARS-CoV2 | Globe Biotech Ltd | |
| RNA based | Encapsulated mRNA | SARS-CoV2 | CEA | |
| RNA based | Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen | SARS-CoV2 | Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX) | |
| RNA based | ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes for multiple antigens, including the Spike (S) protein. | SARS-CoV2 | Ziphius Vaccines and Ghent University | |
| RNA based | LNP-mRNA | SARS-CoV2 | Multiple candidates | Certest Biotec |